Eli Lilly and Company vs Novartis AG: Strategic Comparison
Key Differences at a Glance
| Field | Eli Lilly and Company | Novartis AG |
|---|---|---|
| Revenue | $65.2B | $54.5B |
| Founded | 1876 | 1996 |
| Employees | 50,000 | 75,267 |
| Market Cap | $1.05T | $274.1B |
| Headquarters | United States | Switzerland |
Quick Stats Comparison
| Metric | Eli Lilly and Company | Novartis AG |
|---|---|---|
| Revenue | $65.2B | $54.5B |
| Founded | 1876 | 1996 |
| Headquarters | Indianapolis, Indiana | Basel, Switzerland |
| Market Cap | $1.05T | $274.1B |
| Employees | 50,000 | 75,267 |
Eli Lilly and Company Revenue vs Novartis AG Revenue — Year by Year
| Year | Eli Lilly and Company | Novartis AG | Leader |
|---|---|---|---|
| 2025 | $65.2B | $54.5B | Eli Lilly and Company |
| 2024 | $45.0B | $50.3B | Novartis AG |
| 2023 | $34.1B | $45.4B | Novartis AG |
| 2022 | $28.5B | N/A | Eli Lilly and Company |
| 2021 | $28.3B | N/A | Eli Lilly and Company |
Business Model Breakdown
Overview: Eli Lilly and Company vs Novartis AG
This in-depth comparison examines Eli Lilly and Company and Novartis AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Novartis AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Novartis AG is widest.
On the headline numbers, Eli Lilly and Company reports annual revenue of $65.2B against $54.5B for Novartis AG, while their respective market capitalizations stand at $1.05T and $274.1B. Eli Lilly and Company is headquartered in United States and Novartis AG operates from Switzerland, and those different home markets shape how each company competes.
Eli Lilly and Company: Lilly has transformed from a broad pharmaceutical company into one of the world's most valuable drugmakers because of its cardiometabolic portfolio and pipeline. The core question is how long demand, capacity, and patent protection can compound.
Novartis AG: Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Business Models: How Eli Lilly and Company and Novartis AG Make Money
Eli Lilly and Company and Novartis AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Novartis AG.
Eli Lilly and Company business model: Eli Lilly makes money by discovering, developing, manufacturing, and selling branded prescription medicines. Revenue depends on approved therapies, patents, clinical outcomes, manufacturing capacity, payer access, and global regulatory approvals.
Novartis AG business model: Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
Competitive Advantage: Eli Lilly and Company vs Novartis AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Novartis AG.
Eli Lilly and Company competitive advantage: Lilly's advantage comes from high-value intellectual property, clinical-development execution, biologics manufacturing scale, commercial access, and a concentrated portfolio of medicines with large addressable markets.
Novartis AG competitive advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Growth Strategy: Where Eli Lilly and Company and Novartis AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Novartis AG each plan to expand from here.
Eli Lilly and Company growth strategy: Lilly is investing heavily in manufacturing capacity, next-generation obesity and diabetes drugs, oncology, immunology, neuroscience, and external collaborations to extend growth beyond the first tirzepatide wave.
Novartis AG growth strategy: Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
Financial Picture: Eli Lilly and Company vs Novartis AG
A closer look at the financial trajectory of Eli Lilly and Company and Novartis AG rounds out the comparison.
Eli Lilly and Company: Lilly reported 2025 revenue of $65.179 billion and net income of $20.640 billion. Revenue rose sharply from $45.043 billion in 2024 as demand for Mounjaro and Zepbound expanded.
Novartis AG: Novartis AG reported FY2025 revenue of $54.532B and net income of $13.967B.
Company-Specific SWOT Notes
Eli Lilly and Company
Lilly's tirzepatide franchise represents one of the most commercially successful pharmaceutical launches in history, with combined Mounjaro and Zepbound revenues of approximately $13.
With more than 50 active molecules in clinical development and approximately $9.
Despite a multi-billion-dollar manufacturing expansion program, Lilly's production capacity for tirzepatide and other injectable biologics has lagged the extraordinary demand generated by commercial launches, resulting in drug shortages that have frustrated pa
While tirzepatide's revenue contribution is a strength in the short term, the concentration of approximately 30 percent of Lilly's total revenues in a single molecule creates significant vulnerability to regulatory, safety, manufacturing, or competitive develo
The development of effective oral GLP-1 and incretin-based therapies represents perhaps the largest single commercial opportunity in pharmaceutical history, as an oral formulation would eliminate the injection barrier that limits the addressable market to pati
The Inflation Reduction Act's Medicare drug price negotiation program, which allows the Centers for Medicare and Medicaid Services to directly negotiate prices for high-expenditure drugs, represents a structural threat to Lilly's revenue model in the United St
Novartis AG
After Sandoz and Alcon separations, Novartis is concentrated around branded, higher-margin medicines and specialty platforms.
Large franchises can lose sales quickly when exclusivity ends or payers switch patients to generics and biosimilars.
Radioligand therapy, oncology, immunology, and cardiovascular launches can offset mature-product pressure.
Drug-price controls, reimbursement restrictions, safety findings, and clinical failures can materially affect growth.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Eli Lilly and Company | Eli Lilly and Company reports the larger revenue base ($65.2B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Eli Lilly and Company | Founded in 1876 vs 1996. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Novartis AG | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Novartis AG | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Eli Lilly and Company | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Eli Lilly and Company reports the larger revenue base ($65.2B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1876 vs 1996. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Eli Lilly and Company or Novartis AG?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Eli Lilly and Company vs Novartis AG
Is Eli Lilly and Company better than Novartis AG?
Verdict: Between Eli Lilly and Company and Novartis AG, Eli Lilly and Company is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Eli Lilly and Company comes out ahead in this Eli Lilly and Company vs Novartis AG comparison.
Who earns more — Eli Lilly and Company or Novartis AG?
Eli Lilly and Company earns more with $65.2B in annual revenue versus Novartis AG's $54.5B. Eli Lilly and Company leads on total revenue based on latest verified figures.
Which company has higher revenue — Eli Lilly and Company or Novartis AG?
Eli Lilly and Company reported $65.2B, while Novartis AG reported $54.5B. The revenue leader is Eli Lilly and Company based on latest verified figures.
Eli Lilly and Company revenue vs Novartis AG revenue — which is higher?
Eli Lilly and Company revenue: $65.2B. Novartis AG revenue: $54.5B. Eli Lilly and Company has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Eli Lilly and Company Annual Filings (10-K, 8-K)
- Eli Lilly and Company Corporate Website
- Eli Lilly and Company Annual Report 2025 - Revenue and Financial Data
- sec.gov
- data.sec.gov
- investor.lilly.com
- finance.yahoo.com
- Novartis AG Corporate Website
- Novartis AG Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novartis.com